ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
The role of neuro-imaging in multiple system atrophy.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multiple system atrophy: cure and care.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental Parkinsonism.NPJ Parkinson's disease · 2026Article
- Balance biomarker for early differentiation of Parkinson's disease and multiple system atrophy with parkinsonian type.Journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuroimaging plays a crucial role in diagnosing multiple system atrophy and monitoring progressive neurodegeneration in this fatal disease. Advanced MRI techniques and post-processing methods have demonstrated significant volume loss and microstructural changes in brain regions well known to be affected by MSA pathology. These observations can be exploited to support the differential diagnosis of MSA distinguishing it from Parkinson's disease and progressive supranuclear palsy with high sensitivity and specificity. Longitudinal studies reveal aggressive neurodegeneration in MSA, with notable atrophy rates in the cerebellum, pons, and putamen. Radiotracer imaging using PET and SPECT has shown characteristic disease-related patterns, aiding in differential diagnosis and tracking disease progression. Future research should focus on early diagnosis, particularly in prodromal stages, and the development of reliable biomarkers for clinical trials. Combining different neuroimaging modalities and machine learning algorithms can enhance diagnostic precision and provide a comprehensive understanding of MSA pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.